HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/5/E1289    most recent 00373.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Basu, A. Articles by Joyner, M. J. Search for Related Content PubMed PubMed Citation Articles by Basu, A. Articles by Joyner, M. J.

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

¹Division of Endocrinology and Metabolism and ²Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota

Submitted 15 June 2007 ; accepted in final form 15 August 2007

Sulfonylureas (SU) with glucagon-like peptide-1 (GLP-1)-based therapy are an emerging therapeutic combination for type 2 diabetes. Prior human studies have hinted at endothelial effects of GLP-1 and SU. To study the endothelial effects of GLP-1 per se and to evaluate the modulatory effects, if any, of SU agents on GLP-1-induced changes in endothelial function, healthy, nondiabetic, normotensive, nonsmokers, age 18–50 yr with no family history of diabetes, were studied. Subjects were randomized to either placebo (n = 10), 10 mg of glyburide (n = 11), or 4 mg of glimepiride (n = 8) orally. Euglycemic somatostatin pancreatic clamp with replacement basal insulin, glucagon, and growth hormone was performed for 240 min. Forearm blood flow (FBF) was measured by venous occlusion plethysmography with graded brachial artery infusions of acetylcholine (Ach) and nitroprusside (NTP) before and after intravenous infusion of GLP-1. GLP-1 (preinfusion 3.4 ± 0.2, postinfusion 25.5 ± 2.8 pM) enhanced (P < 0.03) Ach-mediated vasodilatation (+6.5 ± 1.1 vs. +9.1 ± 1.2 ml·100 ml^–1·min^–1, change from baseline FBF) in those on placebo. However, in contrast, glyburide abolished GLP-1-induced Ach-mediated vasodilatation (+11.7 ± 2.0 vs. +11.7 ± 2.5 ml·100 ml^–1·min^–1). On the other hand, glimepiride did not alter the ability of GLP-1 to enhance Ach-mediated vasodilatation (+7.9 ± 0.5 vs. +10.2 ± 1.3 ml·100 ml^–1·min^–1, P < 0.04). Neither GLP-1 nor SU altered NTP-induced vasodilatation. These data demonstrate that GLP-1 per se has direct beneficial effects on endothelium-dependent vasodilatation in humans that are differentially modulated by SU.

glucagon-like peptide-1; incretin; sulfonylurea; vascular reactivity

This article has been cited by other articles:

				Z. T. Bloomgarden The 6th Annual World Congress on the Insulin Resistance Syndrome Diabetes Care, September 1, 2009; 32(9): e104 - e111. [Full Text] [PDF]

				C. Cabou, G. Campistron, N. Marsollier, C. Leloup, C. Cruciani-Guglielmacci, L. Penicaud, D. J. Drucker, C. Magnan, and R. Burcelin Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity Diabetes, October 1, 2008; 57(10): 2577 - 2587. [Abstract] [Full Text] [PDF]

				A. E. Bharucha, N. Charkoudian, C. N. Andrews, M. Camilleri, D. Sletten, A. R. Zinsmeister, and P. A. Low Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R874 - R880. [Abstract] [Full Text] [PDF]